PTHS Stock Analysis: Buy, Sell, or Hold?
PTHS - Pelthos Therapeutics Inc.
$25.77
-2.23 (-7.96%)
▼
5d:
-11.78%
30d:
-0.88%
90d:
+20.99%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When PTHS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PTHS is down 11.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PTHS is down 11.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PTHS is currently trading at $25.77, which is considered oversold relative to its 30-day fair value range of $26.11 to $28.60.
Technical Outlook: Technically, PTHS is in a uptrend. The price is currently testing key support at $25.25. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $57.71 (+124.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PTHS is in a uptrend. The price is currently testing key support at $25.25. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $57.71 (+124.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$26.11 -
$28.60
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.0%)
- BULLISH: Trading 124.0% below Wall St target ($57.71)
- WARNING: Recommendation downgraded due to -11.8% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$26.11 -
$28.60
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$25.25
Resistance Level
$28.02
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.13
Wall Street Target
$57.71
(+124.0%)
Profit Margin
-186.2%
Share & Embed Analysis
Last updated: July 04, 2026 6:27 PM ET
Data refreshes hourly during market hours. Next update: 7:27 PM
Data refreshes hourly during market hours. Next update: 7:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTHS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Ezra M Friedberg
SELL
558 shares
2026-04-02
Peter Greenleaf
SELL
797 shares
2026-04-02
Richard Malamut
SELL
590 shares
2026-04-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 45 HOLD |
